MTHFR and Hyperkalemia: There was no significant relationship between the MTHFR A1298C polymorphism and myelosuppression, chemotherapy delay, neurotoxicity, hyperkalemia, hypokalemia, infection, mucositis, or nephrotoxicity (P > 0.05).